Baricitinib is a selective and orally bioactive inhibitor of JAK1 and JAK2. It has been approved by FDA for the treatment of rheumatoid arthritis (RA).
Products > Drug Discovery > Impurities > Anti-Inflammatory > Baricitinib and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye